Provided by Tiger Trade Technology Pte. Ltd.

Tradr 2X Long TEM Daily ETF

33.65
+5.2418.44%
Post-market: 32.91-0.7400-2.20%19:52 EDT
Volume:598.38K
Turnover:18.68M
Market Cap:64.89M
PE:- -
High:33.80
Open:27.28
Low:27.28
Close:28.41
52wk High:152.22
52wk Low:11.52
Shares:1.93M
Float Shares:1.93M
Volume Ratio:1.37
T/O Rate:31.03%
Dividend:3.85
Dividend Rate:11.44%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

AI Software Shares Fall. Tempus AI Sinks 9%; ServiceNow Down over 4%; Braze, SoundHound AI, Docusign, BigBear.ai Down over 2%

Tiger Newspress
·
Jul 20

Personalis to be acquired by Tempus AI in merger

TIPRANKS
·
Jul 20

Tempus AI Shares Down 6.4%

THOMSON REUTERS
·
Jul 20

Tempus Publishes Investor Deck on Planned Personalis Acquisition to Expand MRD Testing Platform

Reuters
·
Jul 20

Sector Update: Healthcare

MT Newswires Live
·
Jul 20

Tempus AI Shares Fall 8.5% Premarket After Co to Acquire Personalis in $1.5 Bln Deal

THOMSON REUTERS
·
Jul 20

Tempus to Acquire Personalis for $1.5 Billion

Reuters
·
Jul 20

Tempus AI to acquire Personalis for $16.25 per share

TIPRANKS
·
Jul 20

Tempus AI Agrees to Buy Personalis for USD 16.25 Per Share in USD 1.5 Billion Deal

Reuters
·
Jul 20

Tempus AI Inc - Maximum Exchange Ratio Set at 0.3356 Tempus AI Shares Per Personalis Share

THOMSON REUTERS
·
Jul 20

Tempus - Consideration Structured as 100% Stock, Cash Option Capped at 50%

THOMSON REUTERS
·
Jul 20

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (mrd) into Its Ai-enabled Precision Oncology Platform

THOMSON REUTERS
·
Jul 20

Tempus AI Inc - Cash Consideration Will be Financed with Cash on Hand and Borrowings Under Company's Then Existing Credit Facilities

THOMSON REUTERS
·
Jul 20

Dimon Warns AI Risks

AI Industry Frontlines
·
Jul 17

How Do Tempus AI’s (TEM) NHS Prostate Results Shape Its Clinical Credibility Narrative?

Simply Wall St.
·
Jul 17

AI Trading Has Become a 'Rubber Band,' Goldman Sachs Top Trader: The Question is 'When Will It Snap'

AI Industry Frontlines
·
Jul 17

AI Market Outlook; The Era Of Risk-Free Gains Has Come To An End

AI Industry Frontlines
·
Jul 17

Tempus Cites Real-world UK NHS Study Showing Prostate Pathology AI Changes Diagnosis in 5% of Cases

Reuters
·
Jul 16

Tempus AI is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 16

Tempus AI price target raised to $71 from $68 at TD Cowen

TIPRANKS
·
Jul 15